Beijing Biostar Pharmaceuticals Co., Ltd. announced a correction to its 7 May 2026 disclosure on the proposed Share Option Scheme. The company’s Board acknowledged a clerical error in section 10(b) “Employee Sublimit,” revising the maximum aggregate number of shares that may be granted to any single qualified participant—from the previously stated 10 % to 1 % of the company’s issued share capital.

All other terms of the Share Option Scheme remain unchanged. The Board expressed regret for the typographical mistake and confirmed the accuracy of the updated figures as of 26 May 2026.